CL2004000470A1 - Composicion farmaceutica que contiene acido acetilsalicilico y un inhibidor de la hmg-coa reductasa, para la prevencion de enfermedades cardiovasculares. - Google Patents

Composicion farmaceutica que contiene acido acetilsalicilico y un inhibidor de la hmg-coa reductasa, para la prevencion de enfermedades cardiovasculares.

Info

Publication number
CL2004000470A1
CL2004000470A1 CL200400470A CL2004000470A CL2004000470A1 CL 2004000470 A1 CL2004000470 A1 CL 2004000470A1 CL 200400470 A CL200400470 A CL 200400470A CL 2004000470 A CL2004000470 A CL 2004000470A CL 2004000470 A1 CL2004000470 A1 CL 2004000470A1
Authority
CL
Chile
Prior art keywords
hmg
inhibitor
pharmaceutical composition
composition containing
prevention
Prior art date
Application number
CL200400470A
Other languages
English (en)
Inventor
Wagener Khairy Elmahdi Gilbert
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of CL2004000470A1 publication Critical patent/CL2004000470A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSICION FARMACEUTICA QUE CONTIENE CIDO ACETILSALICILICO (COMPONENTE A), UN INHIBIDOR DE LA HMG-CoA REDUCTASA (CMPONENTE B) Y DADO EL CASO, UNA SUSTANCIA ANTIHIPERTENSIVA (COMPONENTE C) PARA LA PREVENCION PRIMARIA DE ENFERMEDADES CARDIOVASCULARES EN PACIENTES CON RIESGO ALTO DE SUFRIR UNA ENFERMEDAD CARDIOVASCULAR, Y MEDICAMENTOS QUE CONTIENEN ESTA COMPOSICION. EL PROCEDIMIENTO DE PREPARACION CONSISTE EN QUE LOS COMPONENTES SE TRANSFORMAN CON COADYUVANTES Y VEHICULOS EN UNA FORMA DE ADMINISTRACION ADECUADA.
CL200400470A 2003-03-10 2004-03-09 Composicion farmaceutica que contiene acido acetilsalicilico y un inhibidor de la hmg-coa reductasa, para la prevencion de enfermedades cardiovasculares. CL2004000470A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10310286 2003-03-10
DE10315618 2003-04-04
DE2003151648 DE10351648A1 (de) 2003-03-10 2003-11-05 Kombinationspräparate von Acetylsalicylsäure zur primären Prävention von Herzkreislauferkrankungen

Publications (1)

Publication Number Publication Date
CL2004000470A1 true CL2004000470A1 (es) 2005-02-04

Family

ID=32909553

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200400470A CL2004000470A1 (es) 2003-03-10 2004-03-09 Composicion farmaceutica que contiene acido acetilsalicilico y un inhibidor de la hmg-coa reductasa, para la prevencion de enfermedades cardiovasculares.

Country Status (5)

Country Link
AR (1) AR043506A1 (es)
CL (1) CL2004000470A1 (es)
DE (1) DE10351648A1 (es)
PE (1) PE20041062A1 (es)
TW (1) TW200505431A (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006105806A1 (en) * 2005-04-07 2006-10-12 Miso Sabovic Delaying the ageing process and disorders caused by ageing
DE102005049293A1 (de) * 2005-10-15 2007-04-26 Bayer Healthcare Ag Kombinationspräparate von Salzen oder o-Acetylsalicylsäure

Also Published As

Publication number Publication date
PE20041062A1 (es) 2005-02-25
TW200505431A (en) 2005-02-16
AR043506A1 (es) 2005-08-03
DE10351648A1 (de) 2004-09-23

Similar Documents

Publication Publication Date Title
PA8615301A1 (es) Formulaciones farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y prevencion de sindromes coronarios agudos.
BRPI0520669A2 (pt) dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina
IL216931A0 (en) Pharmaceutical formulation that comprisies azelastine and fluticasone and aproduct comprising these as antihistamine and anti - inflammatory agent
DOP2011000040A (es) Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentracion sanguinea de glp-1
DOP2003000614A (es) Derivados de bencimidazol n3 alquilado como inhibidores de mek (n3 alkylated benzimidazole
BR0308613A (pt) Combinação de compostos orgânicos
HN2008001666A (es) Derivados acidos de cicloalquilamino
PA8616201A1 (es) Composiciones farmaceuticas de liberacion sostenida
BRPI0415053A (pt) inibidor de p-glicoproteìna, método para preparar o mesmo e composição farmacêutica que compreende o mesmo
BRPI0508125A (pt) formulação de alcalóide, método para melhorar a eficácia de um alcalóide, uso do produto da reação de um ou mais alcalóides com um mais derivados de fosfato de um ou mais agentes de transferência de elétrons, junto com excipientes e composição farmacêutica
MX2007009032A (es) Formulacion para inyeccion de butanos catecolicos incluyendo compuestos ndga en animales.
ECSP099483A (es) Combinación de un inhibidor de desacetilasa de histona y un antimetabolito
BRPI0513909A (pt) comprimido farmacêutico de camada múltipla para a liberação controlada de ingredientes ativos com solubilidade altamente dependente do ph
DOP2002000373A (es) Composiciones que contienen imidazotriazinona para administración nasal
UY28221A1 (es) Preparados de combinación dee ácido acetilsalicílico para la prevención primaria de enfermedades cardiovasculares
MXPA06011467A (es) Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid).
EA200970353A1 (ru) Комбинированное лекарственное средство
DE602004021713D1 (de) Pharmazeutische formulierungen mit kurzketten-sphingolipiden und ihre verwendung
CY1108413T1 (el) Ενεσιμη φαρμακευτικη συνθεση που περιλαμβανει αιθανολη για την αγωγη των δισκοπαθειων
EP4616860A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING AN AAK1 INHIBITOR
CL2004000470A1 (es) Composicion farmaceutica que contiene acido acetilsalicilico y un inhibidor de la hmg-coa reductasa, para la prevencion de enfermedades cardiovasculares.
EA200500764A1 (ru) Фармацевтические композиции и лекарственные формы для трансбуккальной и сублингвальной доставки тизанидина и способы введения тизанидина сублингвально или трансбуккально
MX2007007610A (es) Regimen de cladribina para tratar esclerosis multiple.
ECSP055963A (es) Uso de dipiradamol en combinación con acido acetilsalicílico y un antagonista de angiotensina ii para la prevención de accidente cerebrovascular
AR028996A1 (es) Uso de una combinacion de inhibidores de mtp e inhibidores de hmg - coa reductasa para la fabricacion de medicamentos, medicamentos que los comprenden y el procedimiento para su preparacion